BiotechTube

Deucravacitinib + Placebo

Phase 2Active
0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Lupus Erythematosus, Discoid

Conditions

Lupus Erythematosus, Discoid, Lupus Erythematosus, Subacute Cutaneous

Trial Timeline

Jul 12, 2021 → Feb 28, 2028

NCT ID
NCT04857034

About Deucravacitinib + Placebo

Deucravacitinib + Placebo is a phase 2 stage product being developed by Bristol Myers Squibb for Lupus Erythematosus, Discoid. The current trial status is active. This product is registered under clinical trial identifier NCT04857034. Target conditions include Lupus Erythematosus, Discoid, Lupus Erythematosus, Subacute Cutaneous.

What happened to similar drugs?

8 of 20 similar drugs in Lupus Erythematosus, Discoid were approved

Approved (8) Terminated (7) Active (7)
✅tacrolimusAstellas PharmaApproved
✅Rosuvastatin + SimvastatinAstraZenecaApproved
✅AnifrolumabAstraZenecaApproved
✅BMS-986165Bristol Myers SquibbApproved
✅versus hydroxychloroquineSanofiApproved
✅Belimumab plus Early Vaccination + Belimumab plus Late VaccinationGSK plcApproved
✅Placebo plus standard therapy + Belimumab 10 mg/kg plus standard therapy + Standard therapyGSK plcApproved

Hype Score Breakdown

Clinical
12
Activity
12
Company
15
Novelty
0
Community
0

Clinical Trials (4)

NCT IDPhaseStatus
NCT06532136Phase 2Withdrawn
NCT05997277Phase 2Terminated
NCT06042920ApprovedTerminated
NCT04857034Phase 2Active

Competing Products

20 competing products in Lupus Erythematosus, Discoid

See all competitors
ProductCompanyStageHype Score
Tabalumab Auto-Injector + Tabalumab Prefilled SyringeEli LillyPhase 3
32
Baricitinib + PlaceboEli LillyPhase 2
35
DS-7011a + PlaceboDaiichi SankyoPhase 1
29
DS-7011a + PlaceboDaiichi SankyoPhase 1/2
32
tacrolimusAstellas PharmaPhase 3
40
TacrolimusAstellas PharmaPre-clinical
26
tacrolimus capsule + tacrolimus placebo + leflunomide tablet + leflunomide placebo + prednisoneAstellas PharmaPhase 3
32
tacrolimusAstellas PharmaApproved
35
Tacrolimus capsules + Cyclophosphamide injections + PrednisoneAstellas PharmaPhase 3
40
E6742EisaiPhase 1/2
32
Baricitinib + PlaceboEli LillyPhase 3
40
Baricitinib + PlaceboEli LillyPhase 3
32
LY2127399 + Placebo every 2 weeks + Placebo every 4 weeks + Standard of CareEli LillyPhase 3
40
LY3361237 + PlaceboEli LillyPhase 2
27
LY2127399 + PlaceboEli LillyPhase 3
32
LY3361237 + PlaceboEli LillyPhase 1
29
LY2127399 + Placebo every 2 weeks + Placebo every 4 weeksEli LillyPhase 3
40
Baricitinib + PlaceboEli LillyPhase 3
32
LY3471851 + PlaceboEli LillyPhase 1
29
LY3471851 + PlaceboEli LillyPhase 2
35